The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback